U.S. patent application number 10/238116 was filed with the patent office on 2003-04-17 for detection of melanoma.
This patent application is currently assigned to The Regents of the University of California. Invention is credited to Bastian, Boris, Pinkel, Daniel.
Application Number | 20030073119 10/238116 |
Document ID | / |
Family ID | 23036339 |
Filed Date | 2003-04-17 |
United States Patent
Application |
20030073119 |
Kind Code |
A1 |
Bastian, Boris ; et
al. |
April 17, 2003 |
Detection of melanoma
Abstract
The present invention provides methods of screening for the
presence of premalignant melanocytes in a sample from a patient.
The methods comprise contacting a nucleic acid sample from a
biological sample from the patient with a probe which binds
selectively to a target polynucleotide sequence on a chromosomal
region which is amplified in melanoma cells.
Inventors: |
Bastian, Boris; (San
Francisco, CA) ; Pinkel, Daniel; (Walnut Creek,
CA) |
Correspondence
Address: |
TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO
CA
94111-3834
US
|
Assignee: |
The Regents of the University of
California
Oakland
CA
|
Family ID: |
23036339 |
Appl. No.: |
10/238116 |
Filed: |
September 9, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10238116 |
Sep 9, 2002 |
|
|
|
09271619 |
Mar 17, 1999 |
|
|
|
6465180 |
|
|
|
|
Current U.S.
Class: |
435/6.14 |
Current CPC
Class: |
C12Q 2600/156 20130101;
C12Q 1/6886 20130101; C12Q 2549/125 20130101 |
Class at
Publication: |
435/6 |
International
Class: |
C12Q 001/68 |
Claims
What is claimed is:
1. A method of screening for the presence of a melanoma in a skin
sample that is suspected of being malignant, the method comprising:
contacting a nucleic acid sample from the skin sample with a probe
that binds selectively to a target cyclin D1 polynucleotide
sequences on chromosomal region 11q13, wherein the probe is
contacted with the sample under conditions in which the probe binds
selectively with the target cyclin D1 polynucleotide sequence to
form a stable hybridization complex; and detecting an increase in
the amount of hybridization complex relative to normal, thereby
detecting the presence of melanoma.
2. The method of claim 1, wherein the nucleic acid sample is
contacted with a second probe that binds selectively to a second
target polynucleotide sequence on a chromosomal region selected
from the group consisting of 11p15, 22q12, 7p, 6p, 1q, 12q14, and
5p, wherein the second probe is contacted with the sample under
conditions in which the second probe binds selectively with the
second target polynucleotide sequence to form a stable
hybridization complex.
3. The method of claim 1, wherein the melanoma is acral
melanoma.
4. The method of claim 1, wherein the nucleic acid sample is a
metaphase spread or an interphase nucleus.
5. The method of claim 1, wherein the nucleic acid sample is from
morphologically normal cells adjacent to a lesion suspected of
being melanoma.
6. The method of claim 1, further comprising contacting the sample
with a reference probe.
7. The method of claim 1, further comprising the step of blocking
the hybridization capacity of repetitive sequences in the nucleic
acid sample.
8. The method of claim 6, wherein unlabeled blocking nucleic acids
comprising repetitive sequences are contacted with the sample.
9. The method of claim 7, wherein the unlabeled blocking nucleic
acids are Cot-1 DNA.
10. The method of claim 1, wherein probe is bound to a solid
substrate.
11. The method of claim 10, wherein the probe is a member of an
array.
12. A method of screening for the presence of melanoma in a skin
sample from a patient, the method comprising: detecting an increase
in the amount of cyclin D1 in the sample relative to normal,
thereby detecting the presence of melanoma.
13. The method of claim 12, wherein the melanoma is acral
melanoma.
14. The method of claim 12, wherein the skin sample is from
morphologically normal cells adjacent to a lesion suspected of
being melanoma.
15. The method of claim 12, wherein the increase in the amount of
cyclin D1 is detected using an immunological method.
Description
BACKGROUND OF THE INVENTION
[0001] Melanoma refers to malignant neoplasms of melanocytes. Its
proper diagnosis and early treatment by complete excision is of
great importance because advanced melanoma has a poor prognosis and
most melanomas are curable if excised in their early stages. In
most instances the transformed melanocytes produce increased
amounts of pigment so that the area involved can easily be seen by
the clinician. When the excision margins of a melanoma are
identified based on this macroscopic appearance and no margin of
seemingly uninvolved skin is excised, melanoma has the risk of
local recurrence.
[0002] This has led to the recommendation to remove a safety margin
of normal skin that varies from 0.5 to 3 cm depending on the
thickness of the primary tumor (Wingo, P. A. et al., Cancer
82:1197-207 (1998); Rigel, D. S. et al., J Am Acad Dermatol
34:839-47 (1996); McGovern, V. J. et al., Cancer 32:1446-57
(1973)). It is obvious that the resulting defect inflicted by the
excision can be considerable. If a melanoma measuring 2 cm in
diameter that has a thickness of >4 mm is to be excised under
the current guidelines, the resulting defect would be 8 cm (2+3+3
cm) in diameter. The closure of excisions with 2-3 cm margins
usually require skin grafting and have the potential of adverse
consequences such as unsatisfactory cosmetic result, increased
morbidity and costs, and sometimes permanent functional impairment.
Even with "adequate" safety margins, the melanoma can recur
locally.
[0003] Obviously, it would be desirable if the margins could be
tailored to the needs of the individual patient's tumor.
Unfortunately, so far, no technique exists that is able to detect
the extent of a tumor accurately. In some types of melanomas the
horizontally expanding portion of the tumor mainly consists of
single melanocytes along the basal layer of the epidermis. These
melanoma types are referred to as lentiginous melanomas. In these,
the amount of atypical cells often gradually diminishes towards the
margins so that it can be difficult or impossible for the
pathologist to determine the border of the melanoma. However,
current thinking implies that in most instances, the extent of a
melanoma can be assessed by pathology. The fact that the removal of
a margin of "healthy" skin reduces the recurrence rate, however,
suggests that this skin is actually not healthy but contains
residual melanoma which is undetectable by current methods.
[0004] The identification of useful means by which morphologically
normal premalignant cells that have the capacity to form melanomas
can be identified. The present invention addresses these and other
needs.
SUMMARY OF THE INVENTION
[0005] The present invention provides methods of screening for the
presence of premalignant melanocytes in a sample from a patient.
The methods comprise contacting a nucleic acid sample from a
biological sample from the patient with a probe which binds
selectively to a target polynucleotide sequence on a chromosomal
region which is amplified in melanoma cells. Usually, the copy
number of the target sequence is determined. The nucleic acid
sample is typically from morphologically normal cells adjacent to a
melanoma lesion in the patient.
[0006] In the methods, the probe is contacted with the sample under
conditions in which the probe binds selectively with the target
polynucleotide sequence to form a stable hybridization complex and
the formation of a hybridization complex is detected. The target
sequence is selected from the group consisting of 11p15, 11q13,
22q12, 7p, 6p, 1q, 12q14, and 5p.
[0007] The nature of the nucleic acid sample is not critical to the
invention. In some embodiments, the nucleic acid sample is a
metaphase spread or an interphase nucleus. Typically, the probe is
labeled e.g. with a fluorescent label. The label may be a direct
label. Usually, a reference probe to a second chromosomal region
(e.g. a centromere) is used in the methods as an internal control.
In these embodiments, the second probe is labeled with a
fluorescent label distinguishable from the label on the probe that
selectively hybridizes to the target polynucleotide sequence.
[0008] In some embodiments, the probe may include repetitive
sequences. In this case, the methods may further comprising the
step of blocking the hybridization capacity of repetitive sequences
the probe Unlabeled blocking nucleic acids comprising repetitive
sequences (e.g. Cot-1 DNA) can be contacted with the sample for
this purpose/
[0009] The nucleic acid hybridization can be carried out in a
number of formats. For instance, the hybridization may be an in
situ hybridization. In some embodiments, the probe is bound to a
solid substrate e.g. in as a member of a nucleic acid array.
[0010] Definitions
[0011] To facilitate understanding the invention, a number of terms
are defined below.
[0012] The term "amplicon" as used herein refers to a region of
genomic nucleic acid which, when present in altered copy number, is
associated with cancer. For example, the invention provides nucleic
acid sequences which, when present in aberrant copy number, are
associated with melanomas.
[0013] An "animal" refers to a member of the kingdom Animalia,
characterized by multicellularity, the possession of a nervous
system, voluntary movement, internal digestion, etc. An "animal"
can be a human or other mammal. Preferred animals include humans,
non-human primates, and other mammals. Thus, it will be recognized
that the methods of this invention contemplate veterinary
applications as well as medical applications directed to
humans.
[0014] A "cancer" in an animal refers to the presence of cells
possessing characteristics typical of cancer-causing cells, such as
uncontrolled proliferation, immortality, metastatic potential,
rapid growth and proliferation rate, and certain characteristic
morphological features. Often, cancer cells will be in the form of
a tumor, but such cells may exist alone within an animal, or may be
a non-tumorigenic cancer cell, such as a leukemia cell. Cancers
include, but are not limited to melanomas, breast cancer, lung
cancer, bronchus cancer, colorectal cancer, prostate cancer,
pancreas cancer, stomach cancer, ovarian cancer, urinary bladder
cancer, brain or central nervous system cancer, peripheral nervous
system cancer, esophageal cancer, cervical cancer, uterine or
endometrial cancer, cancer of the oral cavity or pharynx, liver
cancer, kidney cancer, testis cancer, biliary tract cancer, small
bowel or appendix cancer, salivary gland cancer, thyroid gland
cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, and the
like.
[0015] The phrase "detecting a cancer" refers to the ascertainment
of the presence or absence of cancer in an animal, in this case,
melanoma cells or premalignant melanocytes. "Detecting a cancer"
can also refer to obtaining indirect evidence regarding the
likelihood of the presence of cancerous cells in the animal or to
the likelihood or predilection to development of a cancer.
Detecting a cancer can be accomplished using the methods of this
invention alone, or in combination with other methods or in light
of other information regarding the state of health of the
animal.
[0016] The terms "hybridizing specifically to" and "specific
hybridization" and "selectively hybridize to," as used herein refer
to the binding, duplexing, or hybridizing of a nucleic acid
molecule preferentially to a particular nucleotide sequence under
stringent conditions. The term "stringent conditions" refers to
conditions under which a probe will hybridize preferentially to its
target subsequence, and to a lesser extent to, or not at all to,
other sequences. A "stringent hybridization" and "stringent
hybridization wash conditions" in the context of nucleic acid
hybridization (e.g., as in array, Southern or Northern
hybridizations) are sequence dependent, and are different under
different environmental parameters. An extensive guide to the
hybridization of nucleic acids is found in, e.g., Tijssen (1993)
Laboratory Techniques in Biochemistry and Molecular
Biology--Hybridization with Nucleic Acid Probes part I, chapt 2,
"Overview of principles of hybridization and the strategy of
nucleic acid probe assays," Elsevier, N.Y. ("Tijssen"). Generally,
highly stringent hybridization and wash conditions are selected to
be about 5.degree. C. lower than the thermal melting point
(T.sub.m) for the specific sequence at a defined ionic strength and
pH. The T.sub.m is the temperature (under defined ionic strength
and pH) at which 50% of the target sequence hybridizes to a
perfectly matched probe. Very stringent conditions are selected to
be equal to the T.sub.m for a particular probe. An example of
stringent hybridization conditions for hybridization of
complementary nucleic acids which have more than 100 complementary
residues on an array or on a filter in a Southern or northern blot
is 42.degree. C. using standard hybridization solutions (see, e.g.,
Sambrook (1989) Molecular Cloning: A Laboratory Manual (2nd ed.)
Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press,
NY, and detailed discussion, below), with the hybridization being
carried out overnight. An example of highly stringent wash
conditions is 0.15 M NaCl at 72.degree. C. for about 15 minutes. An
example of stringent wash conditions is a 0.2.times.SSC wash at
65.degree. C. for 15 minutes (see, e.g., Sambrook supra.) for a
description of SSC buffer). Often, a high stringency wash is
preceded by a low stringency wash to remove background probe
signal. An example medium stringency wash for a duplex of, e.g.,
more than 100 nucleotides, is 1.times.SSC at 45.degree. C. for 15
minutes. An example of a low stringency wash for a duplex of, e.g.,
more than 100 nucleotides, is 4.times. to 6.times.SSC at 40.degree.
C. for 15 minutes.
[0017] The term "labeled with a detectable composition", as used
herein, refers to a nucleic acid attached to a detectable
composition, i.e., a label. The detection can be by, e.g.,
spectroscopic, photochemical, biochemical, immunochemical, physical
or chemical means. For example, useful labels include .sup.32p,
.sup.35s, .sup.3H, .sup.14C, .sup.125I, .sup.131I; fluorescent dyes
(e.g., FITC, rhodamine, lanthanide phosphors, Texas red),
electron-dense reagents (e.g. gold), enzymes, e.g., as commonly
used in an ELISA (e.g., horseradish peroxidase, beta-galactosidase,
luciferase, alkaline phosphatase), colorimetric labels (e.g.
colloidal gold), magnetic labels (e.g. Dynabeads.TM.), biotin,
dioxigenin, or haptens and proteins for which antisera or
monoclonal antibodies are available. The label can be directly
incorporated into the nucleic acid, peptide or other target
compound to be detected, or it can be attached to a probe or
antibody that hybridizes or binds to the target. A peptide can be
made detectable by incorporating predetermined polypeptide epitopes
recognized by a secondary reporter (e.g., leucine zipper pair
sequences, binding sites for secondary antibodies, transcriptional
activator polypeptide, metal binding domains, epitope tags). Label
can be attached by spacer arms of various lengths to reduce
potential steric hindrance or impact on other useful or desired
properties. See, e.g., Mansfield (1995) Mol Cell Probes
9:145-156.
[0018] The terms "melanoma" or "cutaneous melanoma" refer to
malignant neoplasms of melanocytes, which are pigment cells present
normally in the epidermis and sometimes in the dermis. There are
four types of cutaneous melanoma: lentigo maligna melanoma,
superficial spreading melanoma (SSM), nodular melanoma, and acral
lentiginous melanoma (AM). Melanoma usually starts as a
proliferation of single melanocytes at the junction of the
epidermis and the dermis. The cells first grow in a horizontal
manner and settle an area of the skin that can vary from a few
millimeters to several centimeters. As noted above, in most
instances the transformed melanocytes produce increased amounts of
pigment so that the area involved can easily be seen by the
clinician.
[0019] The term "nucleic acid" as used herein refers to a
deoxyribonucleotide or ribonucleotide in either single- or
double-stranded form. The term encompasses nucleic acids, i.e.,
oligonucleotides, containing known analogues of natural nucleotides
which have similar or improved binding properties, for the purposes
desired, as the reference nucleic acid. The term also includes
nucleic acids which are metabolized in a manner similar to
naturally occurring nucleotides or at rates that are improved for
the purposes desired. The term also encompasses nucleic-acid-like
structures with synthetic backbones. DNA backbone analogues
provided by the invention include phosphodiester, phosphorothioate,
phosphorodithioate, methylphosphonate, phosphoramidate, alkyl
phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino),
3'-N-carbamate, morpholino carbamate, and peptide nucleic acids
(PNAs); see Oligonucleotides and Analogues, a Practical Approach,
edited by F. Eckstein, IRL Press at Oxford University Press (1991);
Antisense Strategies, Annals of the New York Academy of Sciences,
Volume 600, Eds. Baserga and Denhardt (NYAS 1992); Milligan (1993)
J. Med. Chem. 36:1923-1937; Antisense Research and Applications
(1993, CRC Press). PNAs contain non-ionic backbones, such as
N-(2-aminoethyl) glycine units. Phosphorothioate linkages are
described in WO 97/03211; WO 96/39154; Mata (1997) Toxicol. Appl.
Pharmacol. 144:189-197. Other synthetic backbones encompasses by
the term include methyl-phosphonate linkages or alternating
methylphosphonate and phosphodiester linkages (Strauss-Soukup
(1997) Biochemistry 36:8692-8698), and benzylphosphonate linkages
(Samstag (1996) Antisense Nucleic Acid Drug Dev 6:153-156). The
term nucleic acid is used interchangeably with gene, cDNA, mRNA,
oligonucleotide primer, probe and amplification product.
[0020] The term a "nucleic acid array" as used herein is a
plurality of target elements, each target element comprising one or
more nucleic acid molecules (probes) immobilized on one or more
solid surfaces to which sample nucleic acids can be hybridized. The
nucleic acids of a target element can contain sequence(s) from
specific genes or clones, e.g. from the regions identified here.
Other target elements will contain, for instance, reference
sequences. Target elements of various dimensions can be used in the
arrays of the invention. Generally, smaller, target elements are
preferred. Typically, a target element will be less than about 1 cm
in diameter. Generally element sizes are from 1 .mu.m to about 3
mm, preferably between about 5 .mu.m and about 1 mm. The target
elements of the arrays may be arranged on the solid surface at
different densities. The target element densities will depend upon
a number of factors, such as the nature of the label, the solid
support, and the like. One of skill will recognize that each target
element may comprise a mixture of nucleic acids of different
lengths and sequences. Thus, for example, a target element may
contain more than one copy of a cloned piece of DNA, and each copy
may be broken into fragments of different lengths. The length and
complexity of the nucleic acid fixed onto the target element is not
critical to the invention. One of skill can adjust these factors to
provide optimum hybridization and signal production for a given
hybridization procedure, and to provide the required resolution
among different genes or genomic locations. In various embodiments,
target element sequences will have a complexity between about 1 kb
and about 1 Mb, between about 10 kb to about 500 kb, between about
200 to about 500 kb, and from about 50 kb to about 150 kb.
[0021] The terms "nucleic acid sample" or "sample of human nucleic
acid" as used herein refers to a sample comprising human DNA or RNA
in a form suitable for detection by hybridization or amplification.
Typically, it will be prepared from a tissue sample from a patient
who has or is suspected of having melanoma. The sample will most
usually be prepared from tissue surrounding a melanoma tumor.
[0022] In many instances, the nucleic acid sample will be a tissue
or cell sample prepared for standard in situ hybridization methods
described below. The sample is prepared such that individual
chromosomes remain substantially intact and typically comprises
metaphase spreads or interphase nuclei prepared according to
standard techniques. Alternatively, the nucleic acid may be
isolated, cloned or amplified. It may be, e.g., genomic DNA, mRNA,
or cDNA from a particular chromosome, or selected sequences (e.g.
particular promoters, genes, amplification or restriction
fragments, cDNA, etc.) within particular amplicons or deletions
disclosed here.
[0023] The nucleic acid sample may be extracted from particular
cells or tissues, e.g. melanocytes. Methods of isolating cell and
tissue samples are well known to those of skill in the art and
include, but are not limited to, aspirations, tissue sections,
needle biopsies, and the like. Frequently the sample will be a
"clinical sample" which is a sample derived from a patient,
including sections of tissues such as frozen sections or paraffin
sections taken for histological purposes. The sample can also be
derived from supernatants (of cells) or the cells themselves from
cell cultures, cells from tissue culture and other media in which
it may be desirable to detect chromosomal abnormalities or
determine amplicon copy number. In some cases, the nucleic acids
may be amplified using standard techniques such as PCR, prior to
the hybridization. The sample may be isolated nucleic acids
immobilized on a solid.
[0024] A "premalignant melanocyte" is a morphologically normal cell
that has the capacity to form a malignant melanoma tumor. Such
cells are typically found adjacent to a melanoma tumor. As used
here, "adjacent" means less than 5 cm, usually less than 3 cm, from
the nearest atypical cell in the tumor.
[0025] The term "probe" or a "nucleic acid probe", as used herein,
is defined to be a collection of one or more nucleic acid fragments
whose hybridization to a sample can be detected. The probe may be
unlabeled or labeled as described below so that its binding to the
target or sample can be detected. The probe is produced from a
source of nucleic acids from one or more particular (preselected)
portions of the genome, e.g., one or more clones, an isolated whole
chromosome or chromosome fragment, or a collection of polymerase
chain reaction (PCR) amplification products. The probes of the
present invention are produced from nucleic acids found in the
regions described herein. The probe or genomic nucleic acid sample
may be processed in some manner, e.g., by blocking or removal of
repetitive nucleic acids or eruichment with unique nucleic acids.
The word "sample" may be used herein to refer not only to detected
nucleic acids, but to the detectable nucleic acids in the form in
which they are applied to the target, e.g., with the blocking
nucleic acids, etc. The blocking nucleic acid may also be referred
to separately. What "probe" refers to specifically is clear from
the context in which the word is used. The probe may also be
isolated nucleic acids immobilized on a solid surface (e.g.,
nitrocellulose, glass, quartz, fused silica slides), as in an
array. In some embodiments, the probe may be a member of an array
of nucleic acids as described, for instance, in WO 96/17958.
Techniques capable of producing high density arrays can also be
used for this purpose (see, e.g., Fodor (1991) Science 767-773;
Johnston (1998) Curr. Biol. 8:R171-R174; Schummer (1997)
Biotechniques 23: 1087-1092; Kern (1997) Biotechniques 23: 120-124;
U.S. Pat. No. 5,143,854). One of skill will recognize that the
precise sequence of the particular probes described herein can be
modified to a certain degree to produce probes that are
"substantially identical" to the disclosed probes, but retain the
ability to specifically bind to (i.e., hybridize specifically to)
the same targets or samples as the probe from which they were
derived (see discussion above). Such modifications are specifically
covered by reference to the individual probes described herein.
[0026] "Providing a nucleic acid sample" means to obtain a
biological sample for use in the methods described in this
invention. Most often, this will be done by removing a sample of
cells from an animal, but can also be accomplished by using
previously isolated cells (e.g. isolated by another person), or by
performing the methods of the invention in vivo.
[0027] "Tissue biopsy" refers to the removal of a biological sample
for diagnostic analysis. In a patient with cancer, tissue may be
removed from a tumor, allowing the analysis of cells within the
tumor.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] FIG. 1 shows chromosomal localization of DNA-sequence copy
number changes in 15 AMs and 15 SSMs detected by CGH. Lines to the
right of the chromosome ideograms represent gains, lines to the
left represent losses. Bold lines indicate amplifications.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
[0029] Melanoma incidence has significantly increased over the last
five decades (Wingo, P. A. et al., Cancer 82:1197-207 (1998);
Rigel, D. S. et al., J Am Acad Dermatol 34:839-47 (1996)). It has
long been noted that the clinical and histological presentation of
melanoma is not entirely homogenous but shows patterns of
association between anatomic location, type of sun exposure, age,
as well as ethnicity. These patterns led to a proposal of a
classification of different types of primary cutaneous melanoma:
lentigo maligna, superficial spreading, nodular and acral melanoma
(McGovern, V. J. et al., Cancer 32:1446-57 (1973)). However, since
certain histologic features of these melanoma types overlap and no
independent prognostic differences among the types have been
discovered (Krementz, E. T. et al., Ann Surg 195:632-45 (1982);
Panizzon, R. et al., Schweiz Med Wochenschr 112:612-8 (1982);
Brauninger, H. et al., Hautarzt 45:529-531 (1994)), the
justification for such a classification has become controversial
(Ackerman, A. B. et al., Hum Pathol 17:438-40 (1986); Flotte, T. J.
et al., Hum Pathol 17:441-2 (1986)). Thus there seems to be a
growing tendency among clinicians and pathologists dealing with
melanoma to regard primary cutaneous melanoma as a single disease
entity. Furthermore, human melanoma cell lines used in basic
research usually are not identified based on the type of primary
melanoma they are derived from. Thus clinical practice and basic
research studies on melanoma that do not take into account
potential differences among types of melanoma may be predisposed to
overlook associations that pertain only to certain types and
thereby hamper the progress of research.
[0030] The invention is based on this observation that markers of
regions frequently found to be gained in melanoma (chromosomes
11p15, 11q13, 22q12, 7p, 6p, 1q, 12q14, 5p) can be used to detect
morphologically normal but genomically aberrant cells (referred to
here as premalignant melanocytes) at the margins of excision
specimens with a higher sensitivity than conventional methods.
[0031] DETECTION OF COPY NUMBER
[0032] In one embodiment, the presence of, or premalignant
melanocytes is evaluated simply by a determination of copy number
of the regions identified here. Typically, the regions evaluated
are 11p15, 11q13, 22q12, 7p, 6p, 1q, 12q14, and 5p. Methods of
evaluating the copy number of a particular gene or chromosomal
region are well known to those of skill in the art.
[0033] Hybridization-based assays
[0034] Preferred hybridization-based assays include, but are not
limited to, traditional "direct probe" methods such as Southern
Blots or In Situ Hybridization (e.g., FISH), and "comparative
probe" methods such as Comparative Genomic Hybridization (CGH). The
methods can be used in a wide variety of formats including, but not
limited to substrate- (e.g. membrane or glass) bound methods or
array-based approaches as described below.
[0035] In situ hybridization assays are well known (e.g., Angerer
(1987) Meth. Enzymol 152: 649). Generally, in situ hybridization
comprises the following major steps: (1) fixation of tissue or
biological structure to analyzed; (2) prehybridization treatment of
the biological structure to increase accessibility of target DNA,
and to reduce nonspecific binding; (3) hybridization of the mixture
of nucleic acids to the nucleic acid in the biological structure or
tissue; (4) post-hybridization washes to remove nucleic acid
fragments not bound in the hybridization and (5) detection of the
hybridized nucleic acid fragments. The reagent used in each of
these steps and the conditions for use vary depending on the
particular application.
[0036] In a typical in situ hybridization assay, cells are fixed to
a solid support, typically a glass slide. If a nucleic acid is to
be probed, the cells are typically denatured with heat or alkali.
The cells are then contacted with a hybridization solution at a
moderate temperature to permit annealing of labeled probes specific
to the nucleic acid sequence encoding the protein. The targets
(e.g., cells) are then typically washed at a predetermined
stringency or at an increasing stringency until an appropriate
signal to noise ratio is obtained.
[0037] The probes are typically labeled, e.g., with radioisotopes
or fluorescent reporters. The preferred size range is from about
200 bp to about 1000 bases, more preferably between about 400 to
about 800 bp for double stranded, nick translated nucleic
acids.
[0038] In some applications it is necessary to block the
hybridization capacity of repetitive sequences. Thus, in some
embodiments, human genomic DNA or Cot-1 DNA is used to block
non-specific hybridization.
[0039] In Comparative Genomic Hybridization methods a first
collection of (sample) nucleic acids (e.g. from a possible tumor)
is labeled with a first label, while a second collection of
(control) nucleic acids (e.g. from a healthy cell/tissue) is
labeled with a second label. The ratio of hybridization of the
nucleic acids is determined by the ratio of the two (first and
second) labels binding to each fiber in the array. Where there are
chromosomal deletions or multiplications, differences in the ratio
of the signals from the two labels will be detected and the ratio
will provide a measure of the copy number.
[0040] Hybridization protocols suitable for use with the methods of
the invention are described, e.g., in Albertson (1984) EMBO J.
3:1227-1234; Pinkel (1988) Proc. Natl. Acad. Sci. USA 85:9138-9142;
EPO Pub. No. 430,402; Methods in Molecular Biology, Vol. 33: In
Situ Hybridization Protocols, Choo, ed., Humana Press, Totowa, N.J.
(1994), etc. In one particularly preferred embodiment, the
hybridization protocol of Pinkel et al. (1998) Nature Genetics
20:207-211 or of Kallioniemi (1992) Proc. Natl Acad Sci USA
89:5321-5325 (1992) is used.
[0041] The methods of this invention are particularly well suited
to array-based hybridization formats. For a description of one
preferred array-based hybridization system see Pinkel et al. (1998)
Nature Genetics, 20:207-211.
[0042] Arrays are a multiplicity of different "probe" or "target"
nucleic acids (or other compounds) attached to one or more surfaces
(e.g., solid, membrane, or gel). In a preferred embodiment, the
multiplicity of nucleic acids (or other moieties) is attached to a
single contiguous surface or to a multiplicity of surfaces
juxtaposed to each other.
[0043] In an array format a large number of different hybridization
reactions can be run essentially "in parallel." This provides
rapid, essentially simultaneous, evaluation of a number of
hybridizations in a single "experiment". Methods of performing
hybridization reactions in array based formats are well known to
those of skill in the art (see, e.g., Pastinen (1997) Genome Res.
7:606-614; Jackson (1996) Nature Biotechnology 14:1685; Chee (1995)
Science 274:610; WO 96/17958.
[0044] Arrays, particularly nucleic acid arrays can be produced
according to a wide variety of methods well known to those of skill
in the art. For example, in a simple embodiment, "low density"
arrays can simply be produced by spotting (e.g. by hand using a
pipette) different nucleic acids at different locations on a solid
support (e.g. a glass surface, a membrane, etc.).
[0045] This simple spotting, approach has been automated to produce
high density spotted arrays (see, e.g., U.S. Pat. No: 5,807,522).
This patent describes the use of an automated systems that taps a
microcapillary against a surface to deposit a small volume of a
biological sample. The process is repeated to generate high density
arrays. Arrays can also be produced using oligonucleotide synthesis
technology. Thus, for example, U.S. Pat. No. 5,143,854 and PCT
patent publication Nos. WO 90/15070 and 92/10092 teach the use of
light-directed combinatorial synthesis of high density
oligonucleotide arrays.
[0046] In another embodiment the array., particularly a spotted
array, can include genomic DNA, e.g. overlapping clones that
provide a high resolution scan of the amplicon corresponding to the
region of interest. Amplicon nucleic acid can be obtained from,
e.g., MACs, YACs, BACs, PACs, PIs, cosmids, plasmids, inter-Alu PCR
products of genomic clones, restriction digests of genomic clone,
cDNA clones, amplification (e.g., PCR) products, and the like.
[0047] In various embodiments, the array nucleic acids are derived
from previously mapped libraries of clones spanning or including
the target sequences of the invention, as well as clones from other
areas of the genome, as described below. The arrays can be
hybridized with a single population of sample nucleic acid or can
be used with two differentially labeled collections (as with an
test sample and a reference sample).
[0048] Many methods for immobilizing nucleic acids on a variety of
solid surfaces are known in the art. A wide variety of organic and
inorganic polymers; as well as other materials, both natural and
synthetic, can be employed as the material for the solid surface.
Illustrative solid surfaces include, e.g., nitrocellulose, nylon,
glass, quartz, diazotized membranes (paper or nylon), silicones,
polyformaldehyde, cellulose, and cellulose acetate. In addition,
plastics such as polyethylene, polypropylene, polystyrene, and the
like can be used. Other materials which may be employed include
paper, ceramics, metals, metalloids, semiconductive materials,
cermets or the like. In addition, substances that form gels can be
used. Such materials include, e.g., proteins (e.g., gelatins),
lipopolysaccharides, silicates, agarose and polyacrylamides. Where
the solid surface is porous, various pore sizes may be employed
depending upon the nature of the system.
[0049] In preparing the surface, a plurality of different materials
may be employed, particularly as laminates, to obtain various
properties. For example, proteins (e.g., bovine serum albumin) or
mixtures of macromolecules (e.g., Denhardt's solution) can be
employed to avoid non-specific binding, simplify covalent
conjugation, enhance signal detection or the like. If covalent
bonding between a compound and the surface is desired, the surface
will usually be polyfunctional or be capable of being
polyfunctionalized. Functional groups which may be present on the
surface and used for linking can include carboxylic acids,
aldehydes, amino groups, cyano groups, ethylenic groups, hydroxyl
groups, mercapto groups and the like. The manner of linking a wide
variety of compounds to various surfaces is well known and is amply
illustrated in the literature.
[0050] For example, methods for immobilizing nucleic acids by
introduction of various functional groups to the molecules is known
(see, e.g., Bischoff (1987) Anal. Biochem., 164:336-344; Kremsky
(1987) Nucl. Acids Res. 15:2891-2910). Modified nucleotides can be
placed on the target using PCR primers containing the modified
nucleotide, or by enzymatic end labeling with modified nucleotides.
Use of glass or membrane supports (e.g., nitrocellulose, nylon,
polypropylene) for the nucleic acid arrays of the invention is
advantageous because of well developed technology employing manual
and robotic methods of arraying targets at relatively high element
densities. Such membranes are generally available and protocols and
equipment for hybridization to membranes is well known.
[0051] Target elements of various sizes, ranging from 1 mm diameter
down to 1 .mu.m can be used. Smaller target elements containing low
amounts of concentrated, fixed probe DNA are used for high
complexity comparative hybridizations since the total amount of
sample available for binding to each target element will be
limited. Thus it is advantageous to have small array target
elements that contain a small amount of concentrated probe DNA so
that the signal that is obtained is highly localized and bright.
Such small array target elements are typically used in arrays with
densities greater than 10.sup.4/cm.sup.2. Relatively simple
approaches capable of quantitative fluorescent imaging of 1
cm.sup.2 areas have been described that permit acquisition of data
from a large number of target elements in a single image (see,
e.g., Wittrup (1994) Cytometry 16:206-213).
[0052] Arrays on solid surface substrates with much lower
fluorescence than membranes, such as glass, quartz, or small beads,
can achieve much better sensitivity. Substrates such as glass or
fused silica are advantageous in that they provide a very low
fluorescence substrate, and a highly efficient hybridization
environment. Covalent attachment of the target nucleic acids to
glass or synthetic fused silica can be accomplished according to a
number of known techniques (described above). Nucleic acids can be
conveniently coupled to glass using commercially available
reagents. For instance, materials for preparation of silanized
glass with a number of functional groups are commercially available
or can be prepared using standard techniques (see, e.g., Gait
(1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press,
Wash., D.C.). Quartz cover slips, which have at least 10-fold lower
auto fluorescence than glass, can also be silanized.
[0053] Alternatively, probes can also be immobilized on
commercially available coated beads or other surfaces. For
instance, biotin end-labeled nucleic acids can be bound to
commercially available avidin-coated beads. Streptavidin or
anti-digoxigenin antibody can also be attached to silanized glass
slides by protein-mediated coupling using e.g., protein A following
standard protocols (see, e.g., Smith (1992) Science 258:1122-1126).
Biotin or digoxigenin end-labeled nucleic acids can be prepared
according to standard techniques. Hybridization to nucleic acids
attached to beads is accomplished by suspending them in the
hybridization mix, and then depositing them on the glass substrate
for analysis after washing. Alternatively, paramagnetic particles,
such as ferric oxide particles, with or without avidin coating, can
be used.
[0054] In one particularly preferred embodiment, probe nucleic acid
is spotted onto a surface (e.g., a glass or quartz surface). The
nucleic acid is dissolved in a mixture of dimethylsulfoxide (DMSO)
and nitrocellulose and spotted onto amino-silane coated glass
slides. Small capillaries tubes can be used to "spot" the probe
mixture.
[0055] A variety of other nucleic acid hybridization formats are
known to those skilled in the art. For example, common formats
include sandwich assays and competition or displacement assays.
Hybridization techniques are generally described in Hames and
Higgins (1985) Nucleic Acid Hybridization, A Practical Approach,
IRL Press; Gall and Pardue (1969) Proc. Natl. Acad. Sci. USA
63:378-383; and John et al. (1969) Nature 223:582-587.
[0056] Sandwich assays are commercially useful hybridization assays
for detecting or isolating nucleic acid sequences. Such assays
utilize a "capture" nucleic acid covalently immobilized to a solid
support and a labeled "signal" nucleic acid in solution. The sample
will provide the target nucleic acid. The "capture" nucleic acid
and "signal" nucleic acid probe hybridize with the target nucleic
acid to form a "sandwich" hybridization complex. To be most
effective, the signal nucleic acid should not hybridize with the
capture nucleic acid.
[0057] Detection of a hybridization complex may require the binding
of a signal generating complex to a duplex of target and probe
polynucleotides or nucleic acids. Typically, such binding occurs
through ligand and anti-ligand interactions as between a
ligand-conjugated probe and an anti-ligand conjugated with a
signal.
[0058] The sensitivity of the hybridization assays may be enhanced
through use of a nucleic acid amplification system that multiplies
the target nucleic acid being detected. Examples of such systems
include the polymerase chain reaction (PCR) system and the ligase
chain reaction (LCR) system. Other methods recently described in
the art are the nucleic acid sequence based amplification (NASBAO,
Cangene, Mississauga, Ontario) and Q Beta Replicase systems.
[0059] Nucleic acid hybridization simply involves providing a
denatured probe and target nucleic acid under conditions where the
probe and its complementary target can form stable hybrid duplexes
through complementary base pairing. The nucleic acids that do not
form hybrid duplexes are then washed away leaving the hybridized
nucleic acids to be detected, typically through detection of an
attached detectable label. It is generally recognized that nucleic
acids are denatured by increasing the temperature or decreasing the
salt concentration of the buffer containing the nucleic acids, or
in the addition of chemical agents, or the raising of the pH. Under
low stringency conditions (e.g., low temperature and/or high salt
and/or high target concentration) hybrid duplexes (e.g., DNA:DNA,
RNA:RNA, or RNA:DNA) will form even where the annealed sequences
are not perfectly complementary. Thus specificity of hybridization
is reduced at lower stringency. Conversely, at higher stringency
(e.g., higher temperature or lower salt) successful hybridization
requires fewer mismatches.
[0060] One of skill in the art will appreciate that hybridization
conditions may be selected to provide any degree of stringency. In
a preferred embodiment, hybridization is performed at low
stringency to ensure hybridization and then subsequent washes are
performed at higher stringency to eliminate mismatched hybrid
duplexes. Successive washes may be performed at increasingly higher
stringency (e.g., down to as low as 0.25.times.SSPE-T at 37.degree.
C. to 70.degree. C.) until a desired level of hybridization
specificity is obtained. Stringency can also be increased by
addition of agents such as formamide. Hybridization specificity may
be evaluated by comparison of hybridization to the test probes with
hybridization to the various controls that can be present.
[0061] In general, there is a tradeoff between hybridization
specificity (stringency) and signal intensity. Thus, in a preferred
embodiment, the wash is performed at the highest stringency that
produces consistent results and that provides a signal intensity
greater than approximately 10% of the background intensity. Thus,
in a preferred embodiment, the hybridized array may be washed at
successively higher stringency solutions and read between each
wash. Analysis of the data sets thus produced will reveal a wash
stringency above which the hybridization pattern is not appreciably
altered and which provides adequate signal for the particular
probes of interest.
[0062] In a preferred embodiment, background signal is reduced by
the use of a detergent (e.g., C-TAB) or a blocking reagent (e.g.,
sperm DNA, cot-1 DNA, etc.) during the hybridization to reduce
non-specific binding. In a particularly preferred embodiment, the
hybridization is performed in the presence of about 0.1 to about
0.5 mg/ml DNA (e.g., cot-1 DNA). The use of blocking agents in
hybridization is well known to those of skill in the art (see,
e.g., Chapter 8 in P. Tijssen, supra.)
[0063] Methods of optimizing hybridization conditions are well
known to those of skill in the art (see, e.g., Tijssen (1993)
Laboratory Techniques in Biochemistry and Molecular Biology, Vol.
24:Hybridization With Nucleic Acid Probes, Elsevier, N.Y.).
[0064] Optimal conditions are also a function of the sensitivity of
label (e.g., fluorescence) detection for different combinations of
substrate type, fluorochrome, excitation and emission bands, spot
size and the like. Low fluorescence background membranes can be
used (see, e.g., Chu (1992) Electrophoresis 13:105-114). The
sensitivity for detection of spots ("target elements") of various
diameters on the candidate membranes can be readily determined by,
e.g., spotting a dilution series of fluorescently end labeled DNA
fragments. These spots are then imaged using conventional
fluorescence microscopy. The sensitivity, linearity, and dynamic
range achievable from the various combinations of fluorochrome and
solid surfaces (e.g., membranes, glass, fused silica) can thus be
determined. Serial dilutions of pairs of fluorochrome in known
relative proportions can also be analyzed. This determines the
accuracy with which fluorescence ratio measurements reflect actual
fluorochrome ratios over the dynamic range permitted by the
detectors and fluorescence of the substrate upon which the probe
has been fixed.
[0065] Labeling and detection of nucleic acids.
[0066] In a preferred embodiment, the hybridized nucleic acids are
detected by detecting one or more labels attached to the sample or
probe nucleic acids. The labels may be incorporated by any of a
number of means well known to those of skill in the art. Means of
attaching labels to nucleic acids include, for example nick
translation or end-labeling (e.g. with a labeled RNA) by kinasing
of the nucleic acid and subsequent attachment (ligation) of a
nucleic acid linker joining the sample nucleic acid to a label
(e.g., a fluorophore). A wide variety of linkers for the attachment
of labels to nucleic acids are also known. In addition,
intercalating dyes and fluorescent nucleotides can also be
used.
[0067] Detectable labels suitable for use in the present invention
include any composition detectable by spectroscopic, photochemical,
biochemical, immunochemical, electrical, optical or chemical means.
Useful labels in the present invention include biotin for staining
with labeled streptavidin conjugate, magnetic beads (e.g.,
Dynabeads.TM.), fluorescent dyes (e.g., fluorescein, texas red,
rhodarnine, green fluorescent protein, and the like, see, e.g.,
Molecular Probes, Eugene, Oreg., USA), radiolabels (e.g., .sup.3H,
.sup.125I, .sup.35S, .sup.14C, or .sup.32P), enzymes (e.g., horse
radish peroxidase, alkaline phosphatase and others commonly used in
an ELISA), and calorimetric labels such as colloidal gold (e.g.,
gold particles in the 40-80 nm diameter size range scatter green
light with high efficiency) or colored glass or plastic (e.g.,
polystyrene, polypropylene, latex, etc.) beads. Patents teaching
the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752;
3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.
[0068] A fluorescent label is preferred because it provides a very
strong signal with low background. It is also optically detectable
at high resolution and sensitivity through a quick scanning
procedure. The nucleic acid samples can all be labeled with a
single label, e.g., a single fluorescent label. Alternatively, in
another embodiment, different nucleic acid samples can be
simultaneously hybridized where each nucleic acid sample has a
different label. For instance, one target could have a green
fluorescent label and a second target could have a red fluorescent
label. The scanning step will distinguish cites of binding of the
red label from those binding the green fluorescent label. Each
nucleic acid sample (target nucleic acid) can be analyzed
independently from one another.
[0069] Suitable chromogens which can be employed include those
molecules and compounds which absorb light in a distinctive range
of wavelengths so that a color can be observed or, alternatively,
which emit light when irradiated with radiation of a particular
wave length or wave length range, e.g., fluorescers.
[0070] Desirably, fluorescers should absorb light above about 300
nm, preferably about 350 nm, and more preferably above about 400
nm, usually emitting at wavelengths greater than about 10 nm higher
than the wavelength of the light absorbed. It should be noted that
the absorption and emission characteristics of the bound dye can
differ from the unbound dye. Therefore, when referring to the
various wavelength ranges and characteristics of the dyes, it is
intended to indicate the dyes as employed and not the dye which is
unconjugated and characterized in an arbitrary solvent.
[0071] Fluorescers are generally preferred because by irradiating a
fluorescer with light, one can obtain a plurality of emissions.
Thus, a single label can provide for a plurality of measurable
events.
[0072] Detectable signal can also be provided by chemiluminescent
and bioluminescent sources. Chemiluminescent sources include a
compound which becomes electronically excited by a chemical
reaction and can then emit light which serves as the detectable
signal or donates energy to a fluorescent acceptor. Alternatively,
luciferins can be used in conjunction with luciferase or lucigenins
to provide bioluminescence. Spin labels are provided by reporter
molecules with an unpaired electron spin which can be detected by
electron spin resonance (ESR) spectroscopy. Exemplary spin labels
include organic free radicals, transitional metal complexes,
particularly vanadium, copper, iron, and manganese, and the like.
Exemplary spin labels include nitroxide free radicals.
[0073] The label may be added to the target (sample) nucleic
acid(s) prior to, or after the hybridization. So called "direct
labels" are detectable labels that are directly attached to or
incorporated into the target (sample) nucleic acid prior to
hybridization. In contrast, so called "indirect labels" are joined
to the hybrid duplex after hybridization. Often, the indirect label
is attached to a binding moiety that has been attached to the
target nucleic acid prior to the hybridization. Thus, for example,
the target nucleic acid may be biotinylated before the
hybridization. After hybridization, an avidin-conjugated
fluorophore will bind the biotin bearing hybrid duplexes providing
a label that is easily detected. For a detailed review of methods
of labeling nucleic acids and detecting labeled hybridized nucleic
acids see Laboratory Techniques in Biochemistry and Molecular
Biology, Vol. 24: Hybridization With Nucleic Acid Probes, P.
Tijssen, ed. Elsevier, N.Y., (1993)).
[0074] Fluorescent labels are easily added during an in vitro
transcription reaction. Thus, for example, fluorescein labeled UTP
and CTP can be incorporated into the RNA produced in an in vitro
transcription.
[0075] The labels can be attached directly or through a linker
moiety. In general, the site of label or linker-label attachment is
not limited to any specific position. For example, a label may be
attached to a nucleoside, nucleotide, or analogue thereof at any
position that does not interfere with detection or hybridization as
desired. For example, certain Label-ON Reagents from Clontech (Palo
Alto, Calif.) provide for labeling interspersed throughout the
phosphate backbone of an oligonucleotide and for terminal labeling
at the 3' and 5' ends. As shown for example herein, labels can be
attached at positions on the ribose ring or the ribose can be
modified and even eliminated as desired. The base moieties of
useful labeling reagents can include those that are naturally
occurring or modified in a manner that does not interfere with the
purpose to which they are put. Modified bases include but are not
limited to 7-deaza A and G, 7-deaza-8-aza A and G, and other
heterocyclic moieties.
[0076] It will be recognized that fluorescent labels are not to be
limited to single species organic molecules, but include inorganic
molecules, multi-molecular mixtures of organic and/or inorganic
molecules, crystals, heteropolyrners, and the like. Thus, for
example, CdSe-CdS core-shell nanocrystals enclosed in a silica
shell can be easily derivatized for coupling to a biological
molecule (Bruchez et al. (1998) Science, 281: 2013-2016).
Similarly, highly fluorescent quantum dots (zinc sulfide-capped
cadmium selenide) have been covalently coupled to biomolecules for
use in ultrasensitive biological detection (Warren and Nie (1998)
Science, 281:2016-2018).
[0077] Amplification-based assays.
[0078] In another embodiment, amplification-based assays can be
used to measure copy number. In such amplification-based assays,
the nucleic acid sequences act as a template in an amplification
reaction (e.g. Polymerase Chain Reaction (PCR). In a quantitative
amplification, the amount of amplification product will be
proportional to the amount of template in the original sample.
Comparison to appropriate (e.g. healthy tissue) controls provides a
measure of the copy number of the desired target nucleic acid
sequence. Methods of "quantitative" amplification are well known to
those of skill in the art. For example, quantitative PCR involves
simultaneously co-amplifying a known quantity of a control sequence
using the same primers. This provides an internal standard that may
be used to calibrate the PCR reaction. Detailed protocols for
quantitative PCR are provided in Innis et al. (1990) PCR Protocols,
A Guide to Methods and Applications, Academic Press, Inc.
N.Y.).
[0079] Other suitable amplification methods include, but are not
limited to ligase chain reaction (LCR) (see Wu and Wallace (1989)
Genomics 4:560, Landegren et al. (1988) Science241:1077, and
Barringer et al. (1990) Gene 89:117, transcription amplification
(Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173), and
self-sustained sequence replication (Guatelli et al. (1990) Proc.
Nat. Acad. Sci. USA 87: 1874).
[0080] DETECTION OF GENE EXPRESSION
[0081] As indicated below, a number of oncogenes are found in the
regions of amplification disclosed here. Thus, oncogene activity
can be detected by, for instance, measuring levels of the gene
transcript (e.g. mRNA), or by measuring the quantity of translated
protein.
[0082] Detection of gene transcripts.
[0083] Methods of detecting and/or quantifying t gene transcripts
using nucleic acid hybridization techniques are known to those of
skill in the art (see Sambrook et al. supra). For example, a
Northern transfer may be used for the detection of the desired mRNA
directly. In brief, the mRNA is isolated from a given cell sample
using, for example, an acid guanidinium-phenol-chloroform
extraction method. The mRNA is then electrophoresed to separate the
mRNA species and the mRNA is transferred from the gel to a
nitrocellulose membrane. As with the Southern blots, labeled probes
are used to identify and/or quantify the target mRNA. In another
preferred embodiment, the gene transcript can be measured using
amplification (e.g. PCR) based methods as described above for
directly assessing copy number of the target sequences.
[0084] Detection of expressed protein
[0085] The "activity" of the target onocgene can also be detected
and/or quantified by detecting or quantifying the expressed
polypeptide. The polypeptide can be detected and quantified by any
of a number of means well known to those of skill in the art. These
may include analytic biochemical methods such as electrophoresis,
capillary electrophoresis, high performance liquid chromatography
(HPLC), thin layer chromatography (TLC), hyperdiffusion
chromatography, and the like, or various immunological methods such
as fluid or gel precipitin reactions, immunodiffusion (single or
double), immunoelectrophoresis, radioimmunoassay (RIA),
enzyme-linked immunosorbent assays (ELISAs), immunofluorescent
assays, western blotting, and the like.
[0086] KITS FOR USE IN DIAGNOSTIC AND/OR PROGNOSTIC
APPLICATIONS.
[0087] For use in diagnostic, research, and therapeutic
applications suggested above, kits are also provided by the
invention. In the diagnostic and research applications such kits
may include any or all of the following: assay reagents, buffers,
nucleic acids for detecting the target sequesences and other
hybridization probes and/or primers. A therapeutic product may
include sterile saline or another pharmaceutically acceptable
emulsion and suspension base.
[0088] In addition, the kits may include instructional materials
containing directions (i.e., protocols) for the practice of the
methods of this invention. While the instructional materials
typically comprise written or printed materials they are not
limited to such. Any medium capable of storing such instructions
and communicating them to an end user is contemplated by this
invention. Such media include, but are not limited to electronic
storage media (e.g., magnetic discs, tapes, cartridges, chips),
optical media (e.g., CD ROM), and the like. Such media may include
addresses to internet sites that provide such instructional
materials.
EXAMPLES
[0089] This example describes detection of regions of chromosomal
abnormality in acral melanoma.
[0090] Acral melanoma (AM) is one type of melanoma that probably
shows the most striking features, that separates it from other,
more common form of cutaneous melanoma. It develops on palmar,
plantar and subungual skin (Arrington, J. H. d. et al., Am J Surg
Pathol 1:131-343 (1977)), sites of predilection that have little
exposure to sunlicht and are protected from ultraviolet radiation
(UV) by a thick stratum corneum. This makes it unlikely that (UV)
plays a role in the pathogenesis of AM. Interestingly, AM is the
most common type of melanoma in dark-skinned peoples (Coleman, W.
P. d. et al., Arch Dermatol 116:773-6 (1980); Kukita, A. et al., J
Invest Dermatol 92:21OS-213S (1989)), although its overall
incidence appears to be similar across all racial groups (Elwood,
J. M. J Invest Dermatol 92:214S-221S (1989)). In a previous study
of 32 randomly selected primary cutaneous melanomas using
comparative genomic hybridization (CGH) (Kallioniemi, A. et al.
Science 258:818-21 (1992)) it was noted that gene amplifications
occurred infrequently in melanomas but that acral melanomas might
have frequent amplifications (Bastian, B. C. et al., Cancer Res
58:2170-5 (1998)). Here we demonstrate that acral melanoma
constitutes a distinct type of primary cutaneous melanoma that is
characterized by a unique type of genomic instability expressed by
frequent high-level amplifications of small genomic regions that
target oncogenes.
[0091] RESULTS
[0092] Matched-pair analysis of AM and SSM using CGH
[0093] Our initial study of a random selection of primary cutaneous
melanoma (Bastian, B. C. et al., Cancer Res 58:2170-5 (1998))
included a single case of AM that differed from the other cases by
the presence of multiple high-level amplifications involving small
chromosomal subregions. To investigate a potential difference in
the pattern of chromosomal aberrations between AM and SSM, the most
frequent type of melanoma, we selected a total of 15 pairs of these
two types of melanoma. To exclude any bias by patient age and tumor
thickness that we had previously found to correlate with the total
number of aberrations, both groups were matched for age and tumor
thickness. The mean age and tumor thickness in the AM group was
72.2 years (range 44-87 years) and 4.6 mm (range 1.3-14 mm), while
it was 70.8 years (range 40-84) and 5.0 mm (range 1.2-20 mm) in the
SSMs.
[0094] The aberrations detected by CGH are summarized in FIG. 1.
Similarities between the two groups are readily apparent. The most
frequent changes in both groups matched our earlier findings
(Bastian, B. C. et al., Cancer Res 58:2170-5 (1998)). Losses of
chromosomes 9p and 10q occurred in {fraction (10/15)} (67%) and
{fraction (7/15)} (47%) of the AMs and {fraction (9/15)} (60%) and
{fraction (7/15)} (47%) of the SSMs, respectively. In contrast,
gains of chromosome 7p, 5p and losses of chromosome 6q were found
more frequently in the AM group (53% vs. 13%, 33% vs. 0%, and 47%
vs. 7% respectively). However, these differences were not
statistically significant given that a total of 39 comparisons
(i.e., the arms of all autosomes) were performed.
[0095] Significant differences between AM and SSM were found when
the total number and types of aberrations in both groups were
analyzed. First, as shown in table 1, the total number of
aberrations was significantly higher in the acral melanomas. This
was true for gains, losses, and most clearly with amplifications
(see Methods for definition). Every acral melanoma had at least one
amplification, while many had multiple amplifications (mean 1.9).
In the AM group, a total of 29 amplifications in the AM involved at
least 14 separate loci. Most frequently, amplifications involved
chromosomes 11q and 22q. However, as can be seen in FIG. 1,
chromosomal regions 5p15, 5p13, 12q13-22, and 16q21-22 were
amplified in more then one tumor. In contrast, only two
amplifications were found in the entire set of SSMs, one in each of
two tumors.
1TABLE 1 Losses Gains No. of amplifications Total No AM 76 67 29
162 ssm 49 33 2 84 p 0.01 0.0004 0.0000002
[0096] In situ detection of amplifications by FISH
[0097] In order to obtain information on the copy number and tissue
distribution of the amplifications, we performed dual-color FISH on
tissue sections of the tumors that showed amplifications by CGH.
The ploidy of the tumors was assessed by using reference probes for
regions that had normal copy number by CGH. A total of 61 FISH
measurements encompassing 18 different loci were performed in the
17 cases in which amplifications were detected by CGH.
[0098] FISH indicated that if the CGH ratio exceeded 1.3 for a
subregion of a chromosomal arm the tumors contained very high copy
number at that locus. For example, in two cases (AM61 and AM63) CGH
showed tumor:reference ratios at chromosomal band 11q13) of 1.5 and
1.3), respectively. The corresponding average number of FISH
signals determined with a probe mapping to 11q13.2 (RMC11p005)
ranged, depending on the location within the tumor, from 6 to
>20 signals in AM61 and was relatively stable at 7 signals in
case AM63. In both cases the reference probes indicated a near
diploid karyotype, i.e. a signal count similar to normal
keratinocytes of the section. The difference in apparent copy
number found by FISH and CGH is due to two major factors. First,
CGH measures the average copy number of sequences within the group
of cells that are analyzed. Thus contamination of the specimen by
normal cells and heterogeneity of amplification level within the
tumor, will result in ratios that underestimate the highest level
that is present. However, CGH also underestimates the level of
amplification when the amplified regions are small (Piper, J. et
al. Cytometry 19:10-26 (1995)). This is due to the complex packing
of the DNA in the metaphase chromosomes to which the probes are
hybridized. This latter reason is probably the dominant factor in
these measurements since in some cases FISH probes, chosen based on
the apparent position of a CGH peak, missed the peak of the
amplified region. This is exemplified by case AM104 which had
amplifications of the distal portions of chromosomes 5p and 6p by
CGH. A probe mapping to 6p25-pter (RMC06B005) showed 1-2 signals
per nucleus, indicating that the amplicon did not involve the
entire distal p-arm of chromosome 6. The distal arm of chromosome
5p was amplified to equal levels by CGH and revealed an average of
10 copies per nucleus with a probe for chromosome 5p15
(RMC05B3326A).
[0099] In most cases, there was limited heterogeneity in the level
of amplification within the tumor. If a radial part of the neoplasm
was present, its cells had signal counts that were not
significantly different from those found in the cells of the
invasive part. Only one case (AM51) showed high nucleus to nucleus
variations of signals with probes for chromosome 7p21 (RMC07B3078A)
and chromosome 12q14 (12B014), i.e., variations from 4 to over 40
and 6 to over 20 signals, respectively. In this case, cells with
high copy numbers of the 12q14 probe were more frequent at the
deeper parts of the tumor whereas signal numbers of 7p21 varied
over the entire tumor.
[0100] Interestingly, in five cases of AM isolated cells with high
signal counts could be detected in the basal layer of the epidermis
up to 5 mm away from the invasive portion of the tumor. In 4 cases
this finding correlated with the presence of scattered, single
melanocytes that histologically showed slightly enlarged,
hyperchromatic nuclei. Case AM59 had amplifications involving
chromosomes 5q11.2-pter, 11p15-pter, and 16q22-qter. The H-ras
oncogene is a likely target of the 11p15 amplicon and we performed
FISH using a green-labeled probe that contained the H-ras gene
(RMC11B022). A red-labeled probe for chromosome 11q that was
unchanged by CGH (RMC 11P014) was used as a reference. Many single
cells with more than 10 green signals and 2-3 reference signals
could be seen in the basal layer over a distance of 5 mm from the
actual tumor. An immunostain with an antibody that detects wild
type and mutant (val-12) H-ras showed strong H-ras expression by
the melanocytes within that region. As can be seen in the labeled
cells did not have atypical nuclei. Outside of the area where the
cells with the amplification were found, no H-ras expression within
basal melanocytes could be detected.
[0101] Mutation analysis of H-ras
[0102] H-ras is the probable target of the amplification of
chromosome 11p15 of case AM59. To support this notion, we searched
for mutations at codons 12, 13 and 61 of H-ras by sequence
analysis. We found a G->T mutation of codon 12 at position 34
leading to Gly12Cys transition. No wild-type sequence was detected.
Of the other cases, informative sequence data was obtained from 22
tumors (12 AMs and 10 SSMa). Case AM61 had a heterozygous A->G
mutation at codon 61 leading to a Gln61Arg transition. The
remaining 21 cases had wild-type sequences.
[0103] Detection of amplifications in AM in-situ
[0104] The finding of amplifications in all AM and the
demonstration of amplifications in the in-situ portion of several
AMs by FISH suggested that amplifications occur early in the
progression of AM. In this event, it would be expected to find
amplifications in AM that have not progressed to an invasive stage.
Therefore, we selected five additional cases of AM in-situ. Those
lesions could not be studied by CGH, because it is not possible to
collect sufficient tumor cells without significant contamination by
normal cells. Instead, we used F SH with markers for the regions
that were most frequently amplified in the invasive AM, namely
11q13) (RMC11P008) and 22q12 (RMC22P004). Three of the five AM
in-situ showed amplification of 11q13, and one case had an
additional amplification of 22q12. The average number of the
amplified signals ranged from six in one case to over ten in the
two other cases. Reference probes did not show increased copy
numbers.
[0105] DISCUSSION
[0106] Our data demonstrates a significantly higher frequency of
gene amplifications in acral melanomas (AM) than in other types of
cutaneous melanoma (100% vs. 15%). Other human cancers such as
glioblastoma, neuroblastomas, and breast cancer have been shown to
have amplifications in up to 50% of cases (Brodeur, G. M. et al.,
(eds. Vogelstein, B. & Kinzler, K, W.) (McGraw-Hill, New York,
1998)). Since amplifications in other cancers can indicate a poor
prognosis (Seeger, R. C. et al., N Engl J Med 313:1111-6 (1985)),
it is currently thought that amplifications represent a late event
in human cancer (Lengauer, C. et al., Nature 396:643-649 (1998)).
In contrast, the detection of amplifications in AM in-situ
demonstrates early development of amplifications in the progression
of this cancer type.
[0107] The occurrence of at least one (mostly several)
amplification of a chromosomal subregion in all sixteen invasive AM
studied so far (including the index case of AM (Bastian, B. C. et
al., Cancer Res 58:2170-5 (1998))) as well as at least three of the
five in-situ AM suggests that gene amplification plays a
fundamental role in this cancer. It is tempting to speculate that a
specific defect occurring early in tumorigenesis leads to the
amplification of genes important in melanocyte transformation. The
frequent amplifications could thus represent a novel type of
chromosomal instability that drives tumor progression, analogous to
aneuploidy due to inactivation of mitotic spindle checkpoints in
colorectal cancer (Lengauer, C., et al., Nature 386:623-7 (1997)).
In support of this hypothesis is the fact that the amplicons in our
cases frequently contain genes that belong to established pathways
in the control of melanocyte growth or cell growth in general. The
most frequently amplified region (11q13) contains the fibroblast
growth factors (FGF) 3 and 4, and cyclin D1. Basic FGF is a
well-known and highly effective mitogen for melanocytes (Halaban,
R., et al., In Vitro Cell Dev Biol 23:47-52 (1987)), and can serve
as an autocrine growth factor in human melanoma (Halaban, R., et
al., Oncogene Res 3:177-86 (1988)). Platelet derived growth factor
(PDGF) has been shown to have autocrine mitogenic properties as
well (Behl, C. et al., Biochem Bioshys Res Commun 193:744-51
(1993), and PDGFA and PDGFB map to 7p22 and 22q12-13, both regions
that are frequently gained or amplified in our AMs. Endothelin-1
another potent growth factor for melanoma (Yada, Y. et al, J Biol
Chem 266:18352-7 (1991)) maps to 6p23-34, a region that is commonly
gained. Other amplicons harbour potential downstream targets of
these factors such as H-ras (1p13.2), H-ras (11p15), and positive
regulators of the cell cycle CDK4 (12q14), ETF4 (16q22) and cyclin
E (19q13). Based on these associations and our finding, of a
mutated H-ras within the amplicon, we feel that it is reasonable to
expect that the other amplified regions do not represent random
genomic "noise", but will be found to contain genes important in
melanoma development. A higher resolution picture of the structure
of the amplicons is currently being obtained by the use of CGH to
microarrays of mapped clones (Pinkel, D. et al., Nat. Genet.
20:207-211 (1998)).
[0108] Most acral melanomas exhibit a radial growth phase in which
the neoplastic melanocytes are arranged as solitary units along the
basal layer of the epidermis. This pattern is referred to as
lentiginous and contrasts with the more frequent finding of single
cells above the dermoepidermal junction in SSM. Therefore, AMs have
also been called acral lentiginous melanoma. However, not all AMs
exhibit a lentiginous growth pattern and indeed some believe that
SSM and nodular melanoma also occur on acral skin (Feibleman, C. E.
et al., Cancer 46:2492-504 (1980); Sondergaard, K. et al., Acta
Pathol Microbiol Scand [A] 88:275-83 (1980)). The distinction
between the patterns of intraepidermal involvement in the various
types of melanoma is far from absolute, and both AM and lentigo
maligna melanoma often show areas of nested growth and cells above
the basal layer above invasive foci. This finding may account for
some of the difficulty that pathologists have in reliably
separating the types of melanoma by light microscopy. Twelve of our
AMs had a lentiginous radial growth phase and in two cases, no
radial growth phase was represented in the blocks so that no such
classification was possible. One case had a predominantly nested
radial growth phase. Amplifications were found in all AMs,
indicating that the amplifier phenotype is present independent of
the growth pattern. All AM cases of the present series were located
on the foot; however the index case that had three amplifications
(Bastian, B. C. et al., Cancer Res 58:2170-5 (1998)) was a
subungual melanoma from the finger. This indicates that the
amplifier phenotype is not restricted to plantar melanomas.
Although it seems likely that the occurrence on glabrous skin is
the common denominator of AM, future studies are warranted to
define their spectrum more completely.
[0109] Until now, controversy existed whether the subtle increase
in the number of melanocytes without or with slight atypia beyond
the unambiguously recognizable radial tumor parts in AM represent
in-situ melanoma or "activated melanocytes" (Mishima, Y. et al.,
Pathology 17:258-65 (1985)). Our finding of amplifications in
single melanocytes up to 5 mm from the invasive tumor parts by FISH
clearly suggests that this phenomenon represents melanoma in-situ
rather than a reactive phenomenon. Melanoma has a well-documented
tendency to recur locally when not excised with a margin of normal
skin (Day, C. L., Jr. et al., J Dermatol Surg Oncol 9:797-801
(1983)). As FISH detected aberrant cells well beyond the area where
atypical cells were obvious histologically, it is possible that
these "satellite" cells represent the source of recurrence. Future
studies are needed to determine whether this observation can help
resolve the controversy over the size of resection margins in
melanoma (Heenan, P. J. J Am Acad Dermatol 35:281-2 (1996)).
[0110] Our data indicates qualitative differences in the type of
chromosomal abnormality in AM compared to other types of melanoma.
In contrast, when the overall pattern of chromosomal gains and
losses shows is considered, AMs and SSMs exhibit more similarities
than differences. Few genomic regions such as chromosomes 5p, 6q,
and 7p showed different frequencies of involvement. This similarity
of the pattern of aberrations could be interpreted as an indication
that genes operating in the same pathways/checkpoints are affected
in melanoma subtypes, but that it is the mode of gene activation
that differs. Gene amplification could be the predominant mode of
oncogene activation in AM whereas in other types it may be
mutations and rearrangements. Tumor progression of subtypes might
later converge to a common final pathway, explaining the similar
clinical course of melanoma subtypes once the disease metastasizes.
If this assumption is correct, the "amplifier phenotype" in AM may
provide a unique opportunity to identify biologically relevant
genes in melanoma progression because the affected genomic regions
are highlighted by small amplifications.
[0111] MATERIAL AND METHODS
[0112] Study populations
[0113] 15 cases that had been archived under the diagnosis of ALM
were randomly selected from the archive material of the Department
of Dermatolocy, University of Wurzburg, the Dermatopathology
Section of the Departments of Patholocy and Dermatology, and the
Melanoma Center of the University of California, San Francisco. Two
acral melanomas (AM) were from the toe, 10 from the sole, and three
were from the foot without further specification. By histology,
twelve AM were of the acral lentiginous type, two were
unclassifiable because the radial portion of the tumors were not
represented in the specimen, and one had overlapping features with
SSM. As controls fifteen cases that were matched for patient age
(.+-.5 years) and tumor thickness (<1.5 mm, 15-4.0 mm, and
>4.0 mm and had been archived as SSM were retrieved.
Histological re-assessment showed typical features of SSM in all
fifteen controls. No tumor had significant solar elastosis
indicative of severe chronic sun damage.
[0114] For the analysis of AM in-situ, five tumors were selected
from the database of the Melanoma Center at the University of
California, San Francisco.
[0115] Comparative genomic hybridization
[0116] DNA Extraction. 30 .mu.m sections were cut from the paraffin
blocks, with a 5 .mu.m section for H&E every 5 sections. The
unstained 30 .mu.m sections were placed on glass slides and an area
of interest was microdissected without de-paraffinizing.
Microdissection was carried out manually under a dissecting
microscope. Depending on the size of the tumor 3-20 unstained
sections were used and regions with a high density of tumor cells
were separated from normal cells. The dissected tumor parts were
collected in tubes and de-paraffinized by washing with xylene and
ethanol. DNA extraction and labeling was performed as published by
Isola et al. 9 Isola, J. et al., Am J Pathol 145:1301-8 (1994)).
Briefly, tissue was incubated until complete digestion (3 days)
with proteinase K (Life Technologies, Inc., Gaithersburg, Md.) in a
50 mM Tris pH8.5, 1 mM EDTA, 0.5% Tween 20 buffer. DNA was
extracted with phenol-chloroform-isoamylalcohol (25:24:1, v/v),
precipitated with 7.5 m ammonium acetate and 100% ethanol, and
resuspended in water. The amount of DNA obtained ranged from 2 to
12 .mu.g.
[0117] CGH. All tumors were measured both with the tumor DNA
labeled with fluorescein-12-dUTP (Dupont Inc., Boston, Mass.), and
reference DNA with Texas red-5-dUTP ("standard" labeling), and with
the labeling reversed. Labeling was performed by Nick translation.
Nick translation conditions were adjusted so that the probe
fragment size after labeling ranged between 800 and 1500 bp. The
hybridization mixture consisted of 200-1000 ng of labeled tumor
DNA, 200 ng inversely labeled normal human reference DNA from
peripheral blood lymphocytes, and 25 3 c, human Cot-1 DNA (Life
Technologies, Inc., Gaithersburg, Md.) dissolved in 10 .mu.l
hybridization buffer (50% formamide, 10% dextrane sulfate, and
2.times.SSC, pH 7.0). Hybridization was carried out for 2-3) days
at 37.degree. C. to normal metaphases (Kallionlemi, A. et al.,
Proc. Natl. Acad. Sci. U.S.A. 91:2156-60 (1994)). All samples were
investigated with a single a batch of metaphase slides. Slides were
washed three times in a washing solution (50% formamide in
2.times.SSC, pH) at 45.degree. C., once in PN buffer (0.1 M
NaH.sub.2PO.sub.4, 0.1 M Na.sub.2FIPO.sub.4, and 0.1% Nonidet P40,
pH 8.0), and once in distilled water (both 10 minutes at room
temperature). After hybridization, slides were counterstained with
4,6-diamino-2-phenylindole in an anti-fade solution. Hybridization
quality was evaluated as published previously (Bastian, B. C. et
al., Cancer Res 58:2170-5 (1998)). Digital images were collected
from five metaphases with a CCD camera (Microimager 1400, Xiliix
Technologies, Vancouver, British Columbia, Canada) on a standard
fluorescence microscope. The average tumor/reference fluorescence
ratios along each chromosome were calculated with custom CGH
analysis software. Measurements were made on at least 4 copies of
each autosome.
[0118] Controls and Threshold Definitions. Normal DNA and DNA from
tumor cell lines with known aberrations were used as controls. We
regarded a region as aberrant when 1) either the standard labeling
or the reverse labeling resulted in a tumor/reference fluorescent
ratios <0.80 or >1.2 or 2) both the standard and the reverse
labeling resulted in a tumor:reference fluorescent ratios <0.85
or >1.15.
[0119] Fluorescence in-situ hybridization (FISH)
[0120] Dual-color FISH was carried out on tissue sections of the
tumors that showed an amplification by CGH. Probes mapping to
amplified regions and reference probes for regions that were
unchanged by CGH analysis were selected from the Laboratories
resource (http://rmc-www.lbl.gov). Probes were labeled with Cy3
(Amersham, Arlincton Heights, Ill.) or with Digoxigenin (Boehringer
Mannheim, Indianapolis Ind.) by nick translation. 6 .mu.m sections
were mounted on positively charged glass slides (Fisher Scientific,
Pittsburgh, Pa.), deparaffinized, and hydrated by decreasing
strength ethanol. Sections were incubated for 2-4 min in 1M sodium
thiocyanate at 80.degree. C., in 4 mg/ml Pepsin in 0.2 N HCl at
37.degree. C. for 4-8 min, dehydrated by increasing strength
ethanol and air-dried. Slides were denatured in 70% formamide,
2.times.SSC pH 7.0 for 5 min at 72.degree. C., and dehydrated again
in a graded ethanol series. 2.5 to 25 ng of each of the labeled
probes together with 20 .mu.g Cot-1 DNA (Life Technologies, Inc.,
Gaithersburg, Md.) were dissolved in 10 .mu.l hybridization buffer
(50% formamide, 10% dextrane sulfate, and 2.times.SSC, pH 7.0) and
denatured for 10 min at 72.degree. C. Hybridization was carried out
for 48-72 hours at 37.degree. C. Slides were washed three times in
washing solution (50% formamide in 2.times.SSC, pH 7.0) at
45.degree. C., once in 2.times.SSC at 45.degree. C., once in
2.times.SSC at room temperature (RT), and once in 0.1% TritonX100
in 4.times.SSC at RT. Subsequently, sections were incubated with
10% BSA in 4.times.SSC in a moist chamber at 37.degree. C., and
then with a FITC labeled anti-digoxigenin antibody (Boehringer
Mannheim, Indianapolis Ind.) diluted in 4.times.SSC with 10% BSA.
Sections were counterstained with 4,6-diamino-2-phenylindole
(Sigma, St. Louis, Miss.) in an anti-fade solution.
[0121] In all experiments keratinocytes of the epidermis adjacent
to the lesion were used as internal controls. As the hybridization
was carried out on sections of 6 .mu.m thickness, many nuclei were
not fully represented in the slide. For counting hybridization
signals, we selected nuclei that appeared minimally truncated when
the focus of the microscope was slightly altered. The nuclear
signal counts in keratinocytes ranged from mean values of 1.6-1.9.
Tumor cells that had average signal counts within that range were
regarded as near diploid.
[0122] Definition of amplifications
[0123] Based on CGH measurements regions were called amplified if
the tumor/reference ratio of a distinct segment of a chromosomal
arm exceeded 1.5 or if the ratio elevation highlighted a sharply
demarcated segment of a chromosomal arm. In most cases both
criteria were met, however, in some tumors the amplified
chromosomal segment was too narrow to yield a ratio >1.5.
Several tumors of the ALM group had copy number increases exceeding
a tumor/reference ratio of 1.5 that involved the entire chromosome.
These changes were not considered as amplifications.
[0124] Based on the FISH experiments, regions exhibiting at least
three times the average signal number of the reference probe were
called amplified.
[0125] Immunohistochemistry
[0126] Immunostaining for human c-H-ras was performed using a mouse
monoclonal antibody against recombinant c-H-ras (val-12) (Dako
Corp., Calpinteria, Calif., Code No. M637, dilution 1:100)
according to standard procedures with the avidin-biotin
immunoperoxidase method using diaminobenzidine as a chromogen.
[0127] DNA Sequence Analysis
[0128] H-ras codon 12 primers were 5'AGGAGACCCTGTAGGAGGA-3'
(forward) and 5'-CGCTAGGCTCACCTCTATAGTG-3' (reverse) and codon 61
primers were 5'-CTGCAGGATTCCTACCGGA-3' and
5'-ACTTGGTGTTGTTGATGGCA-3'. PCR was carried out in a Gene Amp PCR
System 9700 Thermal Cycler (Perkin Elmer) in 25 .mu.l reaction
volumes. Each PCR reaction contained 3.5 mM MgCl.sub.2, 0.2 mM
dNTP, 0.625 U Taq Gold Polymerase (Perkin Elmer), 1X PCR Buffer II,
0.5 .mu.M each of forward and reverse primer, and 50-300 ng of
genomic DNA. PCR cycling conditions were as follows: 95.degree. C.
for 15 min followed by 35 cycles of 95.degree. C. for 15 sec,
55.degree. C for 30 seconds, and 72.degree. C. for 60 seconds, and
a final hold at 72.degree. C. for 10 minutes.
[0129] Prior to sequencing, PCR products were purified using the
PCR product Presequencing kit (Amersham, Arlington Heights, Ill.)
to remove excess primers and nucleotides. Fluorescent DNA
sequencing was carried out using Big Dye dye terminator sequencing
chemistry (PE Applied Biosystems). Briefly, 30-50 ng of purified
PCR product and 3.2 pmoles of sequencing primer were used for
sequencing in a 15 .mu.l reaction according to the manufacturer's
instructions. The sequencing products were purified using a
Sephadex G50 column, dried in a vacuum concentrator and resuspended
in 3 .mu.l of gel loading buffer (83% deionized formamide, 17% gel
loading dye) (PE Applied Biosystems). 0.5 .mu.l of the sample was
then loaded on a denaturing sequence gel on an ABI automated DNA
sequencer. Data was analyzed using the Sequence Analysis 3.0
software from PE Applied Biosystems and all samples were sequenced
in both forward and reverse directions to confirm the
presence/absence of mutations.
[0130] It is understood that the examples and embodiments described
herein are for illustrative purposes only and that various
modifications or changes in light thereof will be suggested to
persons skilled in the art and are to be included within the spirit
and purview of this application and scope of the appended claims.
All publications, patents, and patent applications cited herein are
hereby incorporated by reference in their entirety for all
purposes.
* * * * *
References